Plain-English translation of NCT07345325 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether patients with a staphylococcal infection of a prosthetic heart valve can be treated successfully without rifampin, an antibiotic often used for this condition. Rifampin can cause side effects and interact with other medications, so researchers want to know if leaving it out of the treatment plan works just as well. You would receive standard antibiotics either with or without this medication.
While rifampin is commonly recommended for this type of heart valve infection, it often causes digestive problems, liver issues, and interactions with other drugs—problems that are especially troublesome for patients with prosthetic valves who may be taking multiple medications. A recent study suggested that patients treated without the medication had similar recovery rates, so this larger trial aims to confirm whether the medication is truly necessary.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the standard antibiotic regimen with rifampin or the same regimen without it. You will take your assigned antibiotics as prescribed and keep a daily journal of how you're feeling. You will attend follow-up visits and participate in phone check-ins for at least 6 months to monitor your recovery and watch for any signs of infection returning.
AI-generated summary from trial data · Aug 3, 2026 · Not medical advice
France